Literature DB >> 29434674

Circulating tumor cells in genitourinary tumors.

Francesco Massari1, Vincenzo Di Nunno2, Francesca Comito2, Marta Cubelli2, Chiara Ciccarese3, Roberto Iacovelli3, Michelangelo Fiorentino4, Rodolfo Montironi5, Andrea Ardizzoni2.   

Abstract

Management of advanced urogenital malignancies has profoundly changed in recent years due to the development of novel targeted drugs that have significantly improved patient's clinical outcomes. This process has been made possible mainly thanks to better knowledge of tumor genetic alterations and molecular altered pathways. Despite these remarkable results, several issues such as early detection of the disease as well as the research into early markers of recurrence or disease progression still remain an open challenge for clinical research. The detection of circulating tumor cells and circulating DNA appears an attractive option since it is a minimally invasive approach potentially able to allow clinicians an accurate diagnosis and maybe lead to more customized treatment strategies. This review focuses on the current techniques adopted for the detection and isolation of circulating tumor cells in genitourinary tumors highlighting their present and possible future application in clinical practice.

Entities:  

Keywords:  biomarkers; circulating tumor cells; early diagnosis; prostate cancer; renal cell carcinoma; urothelial cancer

Year:  2017        PMID: 29434674      PMCID: PMC5805009          DOI: 10.1177/1756287217742564

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN: 1756-2872


  58 in total

1.  Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Authors:  Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

2.  Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.

Authors:  Severine Huber; Christian Schwentner; Dirk Taeger; Beate Pesch; Michael Nasterlack; Gabriele Leng; Thomas Mayer; Katarzyna Gawrych; Nadin Bonberg; Martin Pelster; Georg Johnen; Heike Bontrup; Harald Wellhäusser; Hans-Georg Bierfreund; Christian Wiens; Christian Bayer; Friedhelm Eberle; Bernd Scheuermann; Mattias Kluckert; Gerhard Feil; Thomas Brüning; Arnulf Stenzl
Journal:  BJU Int       Date:  2012-02-07       Impact factor: 5.588

3.  Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Authors:  Shannon L Stott; Richard J Lee; Sunitha Nagrath; Min Yu; David T Miyamoto; Lindsey Ulkus; Elizabeth J Inserra; Matthew Ulman; Simeon Springer; Zev Nakamura; Alessandra L Moore; Dina I Tsukrov; Maria E Kempner; Douglas M Dahl; Chin-Lee Wu; A John Iafrate; Matthew R Smith; Ronald G Tompkins; Lecia V Sequist; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Sci Transl Med       Date:  2010-03-31       Impact factor: 17.956

4.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Authors:  Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller
Journal:  Lancet Oncol       Date:  2009-02-11       Impact factor: 41.316

5.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

6.  Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma.

Authors:  Toru Shimazui; Kazuhiro Yoshikawa; Hirotsugu Uemura; Risa Kawamoto; Koji Kawai; Katsunori Uchida; Yoshihiko Hirao; Shinsuke Saga; Hideyuki Akaza
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

7.  UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.

Authors:  Tine Hajdinjak
Journal:  Urol Oncol       Date:  2008-01-15       Impact factor: 3.498

8.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  5 in total

1.  The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.

Authors:  Emne A Abdallah; Alexcia C Braun; Bianca C T C P Flores; Laís Senda; Ana Cláudia Urvanegia; Vinicius Calsavara; Victor Hugo Fonseca de Jesus; Maria Fernanda Arruda Almeida; Maria Dirlei Begnami; Felipe J F Coimbra; Wilson Luiz da Costa; Diana Noronha Nunes; Emmanuel Dias-Neto; Ludmilla T Domingos Chinen
Journal:  Oncologist       Date:  2019-03-07

Review 2.  Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers.

Authors:  Giulia Brisotto; Roberto Guerrieri; Francesca Colizzi; Agostino Steffan; Barbara Montico; Elisabetta Fratta
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.

Authors:  Alessia Cimadamore; Gaetano Aurilio; Franco Nolé; Francesco Massari; Marina Scarpelli; Matteo Santoni; Antonio Lopez-Beltran; Liang Cheng; Rodolfo Montironi
Journal:  Cells       Date:  2020-06-19       Impact factor: 6.600

Review 4.  Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.

Authors:  Vincenzo Di Nunno; Lidia Gatto; Matteo Santoni; Alessia Cimadamore; Antonio Lopez-Beltran; Liang Cheng; Marina Scarpelli; Rodolfo Montironi; Francesco Massari
Journal:  Front Oncol       Date:  2018-09-24       Impact factor: 6.244

Review 5.  Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer.

Authors:  Veronica Mollica; Vincenzo Di Nunno; Alessia Cimadamore; Antonio Lopez-Beltran; Liang Cheng; Matteo Santoni; Marina Scarpelli; Rodolfo Montironi; Francesco Massari
Journal:  Cells       Date:  2019-01-11       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.